TREMFYA® (guselkumab) demonstrates impressive results across biologic-naïve and biologic-refractory patients in Crohn's disease and ulcerative colitis
J&J(JNJ) Prnewswire·2024-10-10 12:00
TREMFYA® is now U.S. FDA-approved for ulcerative colitis and under review for Crohn's disease TREMFYA® is the only IL-23 inhibitor to demonstrate superiority to ustekinumab in the overall population of patients with Crohn's disease, inclusive of those who are biologic-naïve and biologic-refractory Ninety percent more biologic-naïve patients and three times more biologic-refractory patients with ulcerative colitis achieved endoscopic remission with TREMFYA® VIENNA, Austria, Oct. 10, 2024 /PRNewswire/ -- John ...